<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03696680</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A00926-49</org_study_id>
    <nct_id>NCT03696680</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiotherapy for Cerebral Metastases With Recent Hemorrhagic Signal</brief_title>
  <acronym>STEREO-HBM</acronym>
  <official_title>Stereotactic Radiotherapy for Cerebral Metastases With Recent Hemorrhagic Signal: Phase 2 Study in 2 Steps</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ANOCEF/IGCNO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupement Interrégional de Recherche Clinique et d'Innovation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective 2-stage, non-randomized Phase 2 trial evaluates the safety and efficacy of
      FSRT for the management of hemorrhagic brain metastases
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2019</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemorrhagic complication rate (new hemorrhage or increase of hemorrhage)</measure>
    <time_frame>6 months after end of Stereotactic radiation therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Local tumoral response rate defined according to the recommendations of the RECIST criteria</measure>
    <time_frame>6 months after end of Stereotactic radiation therapy</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Hemorrhagic Brain Metastases</condition>
  <arm_group>
    <arm_group_label>FSRT Stereotactic radiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cerebral metastasis (hemorrhagic or otherwise) will be treated by radiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>FSRT Stereotactic radiation therapy</intervention_name>
    <description>For each metastasis, dose of 30 Gy in 3 fractions at 10 Gy / fraction over 7 days</description>
    <arm_group_label>FSRT Stereotactic radiation therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt; 18 years

          -  Performance Status 0 or 1

          -  Patient with less than 4 brain metastases [of a solid tumor with a histologically
             proven diagnosis for the solid tumor; Patients who have had a metastasectomy and 1 to
             3 brain metastatic lesions are eligible.

          -  Brain injury (s) measuring between 5 and 30 mm in diameter

          -  Patient eligible for stereotactic radiotherapy after a decision of the
             multidisciplinary committee

          -  Presence of intra-tumor bleeding signals on at least one brain injury before
             stereotactic irradiation and defined by :

               -  hyperdense lesion on the non-injected CT (treatment scanner) and / or,

               -  spontaneously hyperintense lesion on T1 MRI sequences without gadolinium
                  injection and / or,

               -  lesion with hypo signal on T2 sequences *

          -  Patient with controlled extra-cranial disease under systemic treatment (chemotherapy
             or targeted therapy):

               -  illness in complete response

               -  partial response or stable illness for more than 3 months

          -  Absence of meningeal tumor invasion

          -  Absence of brainstem metastasis

          -  DS-GPA of 3 or more

          -  Patient without concomitant anti-cancer therapy (chemotherapy, hormone therapy,
             immunotherapy, anti-angiogenic or other anti-cancer treatments). Treatments should be
             suspended for at least 7 days before the start of FSRT radiotherapy. The treatment can
             be resumed 7 days after the end of radiotherapy

          -  Patient cooperating sufficiently to perform the treatment with the use of a
             thermoformed mask

          -  Patient whose neuropsychological capacities make it possible to follow the
             requirements of the protocol

          -  Patient affiliated to a social security scheme

          -  Patient giving written consent

        Exclusion Criteria:

          -  Patient with small cell lung cancer, melanoma, germ cell tumors, lymphoma, leukemia
             and multiple myeloma

          -  Patient with a concomitant neurodegenerative disease

          -  Any symptoms not attributable to cerebral metastasis or cancerous pathology and
             requiring long-term use of corticosteroids (regardless of dose)

          -  Contraindication to brain MRI or gadolinium injection

          -  Hemorrhagic disorders other than intra-tumor bleeding from brain lesion (s)

          -  Radiosensitizing systemic disease (Neurofibromatosis ...)

          -  Thrombocytopenia less than 100,000 cells / mm3

          -  Anticoagulant treatment with curative dose, and / or anti-platelet aggregation during
             FSRT. If treatment can be delayed for at least 5 days before starting FSRT and resumed
             2 months after completion of FSRT, the patient is eligible.

          -  Hemorrhagic metastasis (s) of the brainstem

          -  Planning of the treatment on the target metastasis delivering a dose&gt; 5 Gy on other
             metastases concomitant

          -  Patient with prior cerebral stereotactic irradiation

          -  History of total brain irradiation

          -  Evolutionary extra-cranial disease

          -  Any associated geographical, social or psychopathological condition that could
             compromise the patient's ability to participate in the study

          -  Participation in a therapeutic trial within 30 days

          -  Patient deprived of liberty or under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julien GEFRELOT, MD</last_name>
    <phone>0231455020</phone>
    <email>j.geffrelot@baclesse.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dinu STEFAN, MD</last_name>
    <phone>0231455020</phone>
    <email>d.stefan@baclesse.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien GEFFRELOT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe ROYER, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 3, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hemorrhagic</keyword>
  <keyword>brain metastases</keyword>
  <keyword>FSRT</keyword>
  <keyword>Stereotactic radiation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

